Article
Biologic response modulation by tumor necrosis factor alpha (TNF alpha) in a phase Ib trial in cancer patients.
Journal of immunotherapy (Hagerstown, Md. : 1997) - 1 Sept 1997
Logan T F, Gooding W E, Whiteside T L, Ernstoff M S, Kaplan S S, Miketic L, Vlock D R, Tompkins C, Wood D L, Nadler P I, Kirkwood J M
Abstract excerpt
During a phase I study of recombinant human tumor necrosis factor (TNF) in cancer patients, serial immune studies were performed and analyzed for effects of TNF. The TNF (specific activity 9.6 x 10(6) U/mg protein, < 5.0 endotoxin units/mg protein) was given over 2 h intravenously on days 1, 8-12...
Topics
- Dose-Response Relationship, Immunologic
- Drug Administration Schedule
- Humans
- Immunologic Factors
- Immunotherapy
- Interferon-gamma
- Interleukin-2
- Killer Cells, Lymphokine-Activated
- Monocytes
- Multivariate Analysis
